BioAlliance Pharma SA, a specialty pharmaceutical company focused treatment of  infections in cancer and AIDS patients,  announced March 16 the award of €6.4 million in funding from OSEO (the French state innovation agency). The company will devote the funds to the development of its novel therapies for the treatment of invasive cancers.
 
The funding has been awarded to the "Cancer Anti-invasive Program" (CAP) private-public consortium as part of OSEO’s Strategic Industrial Innovation scheme. The consortium , led by BioAlliance Pharma, comprises two small companies (Oroxcell and Xentech) and two mid-sized companies (Novasep and CIT) and two academic centers of excellence, the Ecole Normale Supérieure de Cachan and the Institut Gustave Roussy. The consortium’s total budget over five years is €9.9 million, including a number of grants-in-aid and repayable advances.